Stamey T A, Ekman P E, Blankenstein M A, Cooper E H, Kontturi M, Lilja H, Oesterling J E, Stenman U H, Turkes A
Dept. of Urology, Stanford University, California.
Scand J Urol Nephrol Suppl. 1994;162:73-87; discussion 115-27.
This chapter mainly deals with biochemical aspects on prostate specific antigen (PSA) and its clinical value. To a limited extent, also other tumor markers, which might be of importance in the evaluation of patients with prostate cancer are discussed. In serum, PSA exists in a free form or bound to antichymotrypsin. Interestingly, only 10% of PSA secreted from cancer cells seems to exist in a free form, as compared to 30% of PSA secreted from cells in benign prostatic hyperplasia (BPH). PSA seems to be closely, but not absolutely, related to tumor grade and stage. The mean value of PSA in patients with tumors dominated by Gleason grades 3 or below, was 10 ng/ml, compared to 29 ng/ml in those with higher grades. Patients with PSA values of 50 ng/ml or above almost exclusively had tumor of Gleason grades 4 or 5, and this limit usually reflected a generalized disease. Patients with PSA-values below 10 ng/ml almost exclusively had tumors confined to the prostate gland. In countries where screening for prostate cancer is believed in, it is important to understand that normal cut-off values are related to patient's age. The upper normal limit of males below 50 years of age should be set at 2.5 ng/ml, as compared to 6.5 ng/ml for men over 70 years of age. To improve the value of PSA determination and for scientific purposes, the standardization of the assay is urgently needed and under way. Prostate acid phosphatase (PAP) has in most centres been replaced by PSA. An elevated PAP value, as measured by the enzymatic method, invariably indicates a generalized disease and could thus be used as a complementary informative assay to PSA. Other markers have been used mainly to achieve additional prognostic information. In a multivariate analysis, the non-specific tumor marker neopterin, which reflects the host response to tumor antigens, was closely related to short-term prognosis. Neopterin was followed by thymidine kinase, a protein reflecting the cell turn-over and tumor grade. Also PSA at diagnosis seemed to add some prognostic information, whereas other markers did not.
本章主要探讨前列腺特异性抗原(PSA)的生化特性及其临床价值。在一定程度上,还讨论了其他可能对前列腺癌患者评估具有重要意义的肿瘤标志物。在血清中,PSA以游离形式或与抗胰凝乳蛋白酶结合的形式存在。有趣的是,癌细胞分泌的PSA似乎只有10%以游离形式存在,而良性前列腺增生(BPH)细胞分泌的PSA这一比例为30%。PSA似乎与肿瘤分级和分期密切相关,但并非绝对相关。Gleason分级为3级及以下的肿瘤患者,PSA的平均值为10 ng/ml,而分级较高的患者该值为29 ng/ml。PSA值在50 ng/ml及以上的患者几乎都患有Gleason分级为4级或5级的肿瘤,这一界限通常反映疾病已广泛扩散。PSA值低于10 ng/ml的患者几乎都患有局限于前列腺的肿瘤。在推行前列腺癌筛查的国家,了解正常临界值与患者年龄相关很重要。50岁以下男性的正常上限应设定为2.5 ng/ml,70岁以上男性则为6.5 ng/ml。为提高PSA检测的价值并出于科学目的,该检测方法的标准化亟待开展且正在进行中。在大多数中心,前列腺酸性磷酸酶(PAP)已被PSA取代。通过酶法检测,PAP值升高始终表明疾病已广泛扩散,因此可作为PSA的补充信息检测方法。其他标志物主要用于获取更多的预后信息。在多变量分析中,反映宿主对肿瘤抗原反应的非特异性肿瘤标志物新蝶呤与短期预后密切相关。其次是胸苷激酶,它是一种反映细胞更新和肿瘤分级的蛋白质。诊断时的PSA似乎也能提供一些预后信息,而其他标志物则不然。